Back to Newsroom

Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research

SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s first antibody drug conjugate (ADC) to treat solid tumors was highly effective against ovarian cancer in preclinical xenograft models and had an encouraging safety profile, according to studies presented today in Chicago at the annual meeting of the American Association for Cancer Research and on March 25thin New Orleansat the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.